Top-News

Immunic Aktie News

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX Branche:  Biotechnologie Land:  USA
0,6794 $
-0,0089 $
-1,29%
0,5836 € 21:07:45 Uhr
Depot/Watchlist
Marktkapitalisierung *
66,08 Mio. €
Streubesitz
44,57%
KGV
-0,90
Index-Zuordnung
-

Immunic News

03.06.25 - PR Newswire
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire
02.06.25 - EQS
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor, Scientific and Industry Conferences in June 02.06.2025 / 12:30 CET/CEST The issuer is solely ...
02.06.25 - PR Newswire
Immunic to Participate in Investor, Scientific and Industry Conferences in June
Immunic to Participate in Investor, Scientific and Industry Conferences in June PR Newswire
29.05.25 - PR Newswire
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire
28.05.25 - PR Newswire
Immunic, Inc. Announces Proposed Public Offering
Immunic, Inc. Announces Proposed Public Offering PR Newswire
02.05.25 - EQS
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in May 02.05.2025 / 12:30 CET/CEST The issuer is solely responsible ...
02.05.25 - PR Newswire
Immunic to Participate in Scientific and Industry Conferences in May
Immunic to Participate in Scientific and Industry Conferences in May PR Newswire
30.04.25 - EQS
EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Issuer: Immunic AG / Key word(s): Study results Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis ...
30.04.25 - PR Newswire
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial PR ...
10.04.25 - EQS
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Issuer: Immunic AG / Key word(s): Financing Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments 10.04.2025 / 19:00 ...
10.04.25 - PR Newswire
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments PR Newswire
09.04.25 - EQS
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Issuer: Immunic AG / Key word(s): Financing Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments 09.04.2025 / 14:10 CET/CEST ...
09.04.25 - PR Newswire
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments PR Newswire
01.04.25 - EQS
EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Issuer: Immunic AG / Key word(s): Conference Immunic, Inc. to Participate in Scientific and Industry Conferences in April 01.04.2025 / 12:30 CET/CEST The issuer is solely ...
01.04.25 - PR Newswire
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Immunic, Inc. to Participate in Scientific and Industry Conferences in April PR Newswire
03.03.25 - EQS
EQS-News: Immunic to Participate in Scientific and Investor Conferences in March
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in March 03.03.2025 / 12:30 CET/CEST The issuer is solely responsible ...
03.03.25 - PR Newswire
Immunic to Participate in Scientific and Investor Conferences in March
Immunic to Participate in Scientific and Investor Conferences in March PR Newswire
26.02.25 - EQS
EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Conference/Study Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis ...
26.02.25 - PR Newswire
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis PR Newswire
20.02.25 - EQS
EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Issuer: Immunic AG / Key word(s): Study results Immunic’s Oral IMU-856 Demonstrated Dose-​Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »